Feinberg School of Medicine
Division of Northwestern University
Latest From Feinberg School of Medicine
Tech Transfer Roundup: ProQR Partners With Foundation Fighting Blindness On Rare Vision-Loss Disorder
Galderma unveils seven-year partnership with Mount Sinai and Northwestern in atopic dermatitis. Beacon/Takeda and Zealand/UniQuest tie-ups both address gastrointestinal diseases.
Investors and dealmakers are using recent discoveries about convergences between Gaucher’s disease and Parkinson’s in the lysosome to generate new therapeutic programs. Start-up Lysosomal Therapeutics thinks that the rare disorder can serve as a model system for developing new drugs to increase lysosomal function as a way to treat Parkinson’s disease and possibly other neurodegenerative disorders.
Innovation in arrhythmia monitoring technologies, as well as new research showing how these devices may improve arrhythmia diagnosis and management, particularly in cryptogenic stroke patients, will help drive growth in the market for outpatient ambulatory cardiac monitoring devices, which is valued at approximately $1.5 billion in the US alone.
Despite the availability of new oral medicines, larger advances in MS remain elusive, especially for those with advanced MS. Two nonprofit groups, the National MS Society’s Fast Forward venture arm and the Myelin Repair Foundation, are thinking creatively in different ways – but both spending millions of dollars – to make those breakthroughs come sooner.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.